Logout Lundbeck sites Contact Us
Cipralex is licenced for the treatment of major depressive disorder (MDD)
Significantly higher response and remission rates with escitalopram according to an analysis by Kornstein SG et al.
The more severe the depression is at the beginning of treatment, the more pronounced is the difference in efficacy at study endpoint between escitalopram and its comparators.
Cipralex is significantly more efficacious than paroxetine in the long-term treatment of severely depressed patients.
Cipralex demonstrates higher rates of response and remission as well as a shorter time to symptom relief.